1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
BenQ Medical Technology Corp.

BenQ Medical Technology Corp.

TTPEX:4116
40.10
TWD
0.00
(0.00%)
1.72BMarket Cap
BenQ Medical Technology Corp.
TPEX:4116
(Taipei Exchange)

Recent

price

40.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
15.88
13.57
16.21
21.5
26.8
24.28
19.8
23.37
27.68
30.97
31.44
32.86
98.2
101.94
106.97
117.89
- -
Revenue per Share
2.04
0.71
0.78
1.13
2.06
3.06
1.05
1.05
1.5
1.69
1.39
0.65
4.04
2.57
2.35
1.75
- -
Basic EPS, GAAP
3.92
0.58
2.88
0.18
1.45
-1.69
-2.04
-0.93
1.97
3.32
2.45
1.98
9.04
6.8
1.05
5.82
- -
Free Cash Flow per Basic Share
0.4
1
0.5
0.5
0.59
0.99
1.5
0.7
1
1.35
1.35
1
0.5
2.1
2
1.65
- -
Dividend per Share
13.45
13.21
13.7
14.38
16.06
23.05
22.54
22.82
23.26
23.57
23.65
23.29
33.48
24.68
25.18
25.28
24.74
Book Value per Share
13.45
13.12
13.64
13.5
14.87
22.07
21.53
20.47
21.05
21.56
21.51
21.34
25.66
17.17
16.31
15.7
15.34
Tangible Book Value per Share
37
37
37
37
38
39
44
44
45
45
45
45
45
45
45
45
45
Basic Weighted Avg Shares
595
508
607
806
1,015
938
876
1,037
1,233
1,380
1,401
1,465
4,377
4,543
4,767
5,254
- -
Sales/Revenue/Turnover
12.85
6.88
5.89
5.54
9.37
0.51
6.12
6.67
7.59
8.19
6.95
3.35
8.05
8.03
6.99
6.59
- -
Operating Margin (%)
19
15
16
35
37
31
35
41
48
75
86
101
226
229
255
269
- -
Depreciation Expense
77
27
29
42
78
118
46
47
67
75
62
29
180
115
105
78
- -
Net Income, GAAP
4.41
28.14
24.08
20.48
25.04
10.97
27.49
23.67
19.14
18.99
20.4
20.63
17.82
29.46
27.97
34.96
- -
Effective Tax Rate (%)
12.87
5.26
4.8
5.27
7.68
12.59
5.29
4.5
5.41
5.46
4.43
1.97
4.12
2.52
2.2
1.49
- -
Profit Margin (%)
329
332
300
70
192
448
276
233
390
253
309
407
1,275
1,356
1,330
1,415
1,198
Working Capital
- -
- -
- -
8
4
11
30
60
200
131
189
376
631
1,104
1,145
753
837
LT Debt
504
495
513
539
623
1,026
1,003
1,067
1,092
1,106
1,117
1,100
2,566
2,180
2,300
2,331
2,273
Total Equity
14.97
4.23
4.77
6.06
10.58
11.34
3.5
4.48
5.79
6.74
5.54
2.47
10.78
6.83
5.95
5.17
- -
Return on Invested Capital (%)
15.19
5.06
5.49
7.62
12.44
13.4
4.32
3.87
4.52
4.28
3.12
0.78
0.38
-0.39
-0.07
-0.76
- -
Return on Capital (%)
16.18
5.36
5.79
8.07
13.53
14.44
4.59
4.63
6.49
7.23
5.9
2.76
14.25
8.84
9.44
6.95
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,236
1,182
1,159
LT Borrowings
534
758
628
LT Finance Leases
219
215
209
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
45
Market Capitalization
1,965
1,743
1,716

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,693
3,645
3,523
Cash, Cash Equivalents & STI
1,236
1,131
1,028
Accounts Receivable, Net
969
1,009
1,014
Inventories
893
907
909
Total Current Liabilities
2,277
2,288
2,324
Payables & Accruals
- -
- -
- -
ST Debt
1,236
1,182
1,159
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.23%
24.71%
1.33%
Free Cash Flow
39.67%
136.53%
455.23%
Net Income, GAAP
37.94%
80.22%
-25.43%
Sales/Revenue/Turnover
26.65%
44.46%
10.21%
Total Cash Common Dividend
- -
44.36%
-17.5%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,057
1,176
1,215
1,319
4,767
2025
1,228
1,335
- -
1,375
5,254
2026
1,325
1,429
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.51
0.66
0.6
0.59
2.35
2025
0.5
0.22
- -
0.42
1.75
2026
0.28
1.32
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2
2025
- -
- -
- -
- -
1.65
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
BenQ Medical Technology Corporation (4116.TWO), a subsidiary of Qisda Corporation, manufactures, assembles, maintains, repairs, wholesales, retails, leases and sells medical equipment, consumables and related services; core offerings encompass operating room equipment including electric and manual hydraulic surgical tables, adjustable and single color temperature surgical lights, pendant medical supply units and ICU suspension bridges; diagnostic tools such as portable and cart-based ultrasound systems, diagnostic and surgical medical display monitors, magnetic resonance displays and AI-enabled rehabilitation equipment for long-term care; integrated solutions like the IQOR operating system and neurosurgical navigation robots; medical disposables featuring needle-free IV infusion and anesthesia products including volume metric administration sets, connectors and laryngeal mask airways (LMA), surgical and endoscopy disposables, endoscopic treatment instruments, hemodialyzers, plasmapheresis-related products and blood bags; and medical services comprising pharmaceuticals and consumables integrated supply, equipment leasing, hospital management consulting, hearing services, dietary supplements via brick-and-mortar channels, veterinary drugs and equipment supply chains, clinical laboratory operations, and digital orthodontic materials including whitening trays, braces and mouthguards. The company operates primarily in Taiwan, Mainland China, Thailand, Indonesia and over 50 countries worldwide, with manufacturing sites in Taiwan and China, an R&D center in Taiwan, and sales/service centers across its key markets; it was founded in 1989 as Trident Medical Corp., renamed BenQ Medical Technology Corporation in June 2011, went public in 2015 and is headquartered in Taipei, Taiwan. Recent developments include a March 2025 strategic partnership with Brain Navi Biotechnology to commercialize the NaoTrac neurosurgical navigation robot in China, leveraging BenQ's hospital network and aligning with China's 14th Five-Year Plan for medical equipment; acquisition of K2 International Medical boosting Southeast Asian revenue growth; establishment of new subsidiary KANG YUE MEDICAL CO., LTD.; Shanghai factory certification for surgical lights and tables in Q4 2025 with production line setup for neurosurgical robots; expansion of 3D spinal navigation robots into India and domestic veterinary rehabilitation; addition of endoscopic equipment/consumables, chemotherapy drug dispensing systems and enhanced product lines in Thailand/Indonesia; and entry into clinical laboratories and veterinary supply chains, driving 12% year-over-year revenue growth to NTD 3.9 billion in the first three quarters of 2025.